UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents

Expert opinion on therapeutic patents, 2009-06, Vol.19 (6), p.801-825

2009

Volltextzugriff (PDF)

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

Bioorganic & medicinal chemistry letters, 2008-07, Vol.18 (14), p.4204-4209

2008

Volltextzugriff (PDF)

Synthesis of Mono- and Difluoronaphthoic Acids

Journal of organic chemistry, 2002-02, Vol.67 (4), p.1171-1177

2002

Volltextzugriff (PDF)

The discovery of azepane sulfonamides as potent 11β-HSD1 inhibitors

Bioorganic & medicinal chemistry letters, 2009-08, Vol.19 (16), p.4563-4565

2009

Volltextzugriff (PDF)

Azabicyclic sulfonamides as potent 11β-HSD1 inhibitors

Bioorganic & medicinal chemistry letters, 2010-03, Vol.20 (5), p.1551-1554

2010

Volltextzugriff (PDF)

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

Bioorganic & medicinal chemistry letters, 2008-07, Vol.18 (14), p.4204-4209

2008

Volltextzugriff (PDF)

Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists

Bioorganic & medicinal chemistry letters, 2008-07, Vol.18 (14), p.4199-4203

2008

Volltextzugriff (PDF)

Structure-activity relationship studies: M2 and CCR5 receptor antagonists

Current topics in medicinal chemistry, 2003, Vol.3 (10), p.1155-1169

2003

Volltextzugriff (PDF)

Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED

Bioorganic & medicinal chemistry letters, 2005-05, Vol.15 (9), p.2365-2369

2005

Volltextzugriff (PDF)

SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction

Bioorganic & medicinal chemistry letters, 2004-03, Vol.14 (5), p.1291-1294

2004

Volltextzugriff (PDF)

Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors

Bioorganic & medicinal chemistry letters, 2002-11, Vol.12 (21), p.3149-3152

2002

Volltextzugriff (PDF)

Novel Structure Elucidation of AAL Toxin TA Backbone

Journal of the American Chemical Society, 1994-06, Vol.116 (11), p.4995-4996

1994

Volltextzugriff (PDF)

Improving the Oral Efficacy of CNS Drug Candidates: Discovery of Highly Orally Efficacious Piperidinyl Piperidine M2 Muscarinic Receptor Antagonists

Journal of medicinal chemistry, 2002-12, Vol.45 (25), p.5415-5418

2002

Volltextzugriff (PDF)

Enhancement of pharmacokinetic properties and in vivo efficacy of benzylidene ketal M2 muscarinic receptor antagonists via benzamide modification

Bioorganic & medicinal chemistry letters, 2002-12, Vol.12 (23), p.3479-3482

2002

Volltextzugriff (PDF)

Metabolic stabilization of benzylidene ketal M2 muscarinic receptor antagonists via halonaphthoic acid substitution

Bioorganic & medicinal chemistry letters, 2001-09, Vol.11 (17), p.2311-2314

2001

Volltextzugriff (PDF)

Benzylidene ketal derivatives as M2 muscarinic receptor antagonists

Bioorganic & medicinal chemistry letters, 2000-12, Vol.10 (24), p.2727-2730

2000

Volltextzugriff (PDF)

Azabicyclic sulfonamides as potent 11b-HSD1 inhibitors

Bioorganic & medicinal chemistry letters, 2010-03, Vol.20 (5), p.1551-1554

2010

Volltextzugriff (PDF)

Relative and absolute stereochemistry of the fumonisin B2 backbone

Tetrahedron letters, 1994-09, Vol.35 (37), p.6819-6822

1994

Volltextzugriff (PDF)

11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents

Expert opinion on therapeutic patents, 2009-06, Vol.19 (6), p.801-825

2009

Volltextzugriff (PDF)

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A sub(2A) receptor antagonists

Bioorganic & medicinal chemistry, 2008-07, Vol.18 (14), p.4199-4203

2008

Volltextzugriff (PDF)

Orally active and selective benzylidene ketal M2 muscarinic receptor antagonists for the treatment of Alzheimer's disease

Drug development research, 2002-07, Vol.56 (3), p.310-320

2002

Volltextzugriff (PDF)

Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A 2A receptor antagonists

Bioorganic & medicinal chemistry letters, 2008, Vol.18 (14), p.4199-4203

2008

Volltextzugriff (PDF)

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A 2A receptor antagonists

Bioorganic & medicinal chemistry letters, 2008, Vol.18 (14), p.4204-4209

2008

Volltextzugriff (PDF)

The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors

Bioorganic & medicinal chemistry letters, 2009-08, Vol.19 (16), p.4563-4565

2009

Volltextzugriff (PDF)

Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors

Bioorganic & medicinal chemistry letters, 2010-03, Vol.20 (5), p.1551-1554

2010

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(125)

Publikationsform

Sprache

Englisch
(148)
Japanisch
(20)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

Synthesis of Mono- and Difluoronaphthoic Acids

The discovery of azepane sulfonamides as potent 11β-HSD1 inhibitors

Azabicyclic sulfonamides as potent 11β-HSD1 inhibitors

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists

Structure-activity relationship studies: M2 and CCR5 receptor antagonists

Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED

SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction

Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors

Novel Structure Elucidation of AAL Toxin TA Backbone

Improving the Oral Efficacy of CNS Drug Candidates: Discovery of Highly Orally Efficacious Piperidinyl Piperidine M2 Muscarinic Receptor Antagonists

Enhancement of pharmacokinetic properties and in vivo efficacy of benzylidene ketal M2 muscarinic receptor antagonists via benzamide modification

Metabolic stabilization of benzylidene ketal M2 muscarinic receptor antagonists via halonaphthoic acid substitution

Benzylidene ketal derivatives as M2 muscarinic receptor antagonists

Azabicyclic sulfonamides as potent 11b-HSD1 inhibitors

Relative and absolute stereochemistry of the fumonisin B2 backbone

11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A sub(2A) receptor antagonists

Orally active and selective benzylidene ketal M2 muscarinic receptor antagonists for the treatment of Alzheimer's disease

Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A 2A receptor antagonists

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A 2A receptor antagonists

The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors

Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors

Suchergebnisse filtern